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ABSTRACT 
Many cases of gallstones can be explained in terms of 
the established risk factors, especially obesity. 
However, gallstones develop in some women who are 
not obese, and the causes are unknown. Biochemical 
studies have shown that slow intestinal transit is 
associated with lithogenic bile. We have tested the 
hypothesis that intestinal transit is abnormally slow in 
normal-weight women with gallstones. 
In a population survey, 1058 women aged 25-69 years, 
registered with general practitioners in Bristol, UK, 
underwent cholecystosonography. Gallstones were 
identified in 48 women, of whom 15 were of normal 
weight (body mass index 5 25 kg/m2). These women 
and age-matched controls with healthy gallbladders 
then underwent measurement of whole-gut transit 
time (WGTT); the measurement was done directly 
when possible, or calculated from records of three 
defaecations. The mean WGTT was significantly longer 
in the women with gallstones than in the controls (82 
vs 63 h; mean difference 19, 95% C1 (2-37 h). Stool 
output was also lower in the women with gallstones (74 
[SD 541 vs 141 [56] gper 24 h, p = 0.015). There was no 
significant difference between cases and controls in 
body mass index, waist-hip circumference ratio, parity, 
plasma triglyceride concentration, or alcohol intake. 
Normal-weight women with gallstones tend to have 
slow intestinal transit and this feature could explain 
why they have gallstones. 
COMMENTS 
Concepts of the pathogenesis of cholesterol gallstone 
formation have changed over the past decade, and 
several defects in both the hepatic secretion of lipids and 
gallbladder function have been identified. We know that 
for crystallization of cholesterol monohydrate to  occur, 
bile must be supersaturated with cholesterol and a 
gallbladder nucleating factor accelerating crystallization 
is required. This process may be enhanced by gallbladder 
hypomotility (1). Although many of non-gallstone- 
forming patients have thermodynamically unstable bile, 
it is recognized a priori that bile is unstable in all 
gallstone-forming individuals. Supersaturated bile can 
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occur as a result of an absolute increase in cholesterol 
secretion or a relative increase in the proportion of 
cholesterol to bile salt excretion. Oversecretion of 
cholesterol is considered the main metabolic event in 
women; the major cause of this defect is obesity (2). 
Hypersecretion of cholesterol in obese women may be 
compounded by weight-reduction programs that cause 
further increases in supersaturation of bile with choles- 
terol (3). 
What, then, is the cause of gallstone formation in 
non-obese women? Possible explanations include re- 
duced or altered bile acid pool, delayed gallbladder 
emptying and gallbladder factors that accelerate nucle- 
ation (1). In this study the authors attempted to 
determine whether prolongation of whole-gut transit 
time (WGTT) could be another explanation for choles- 
terol gallstone formation in non-obese women. To study 
this question, these investigators conducted a popu- 
lation survey of 1,058 women. Fifteen of the 48 patients 
with asymptomatic gallstones were of normal weight. 
When WGTT was examined with a radioopaque-marker 
technique or estimates of WGTT were made with 
formulas devised by the authors (41, there appeared to be 
a significant prolongation in transit time in gallstone 
patients compared with age- and weight-matched con- 
trols. Stool weights were also significantly lower in the 
gallstone patients; this may have reflected delayed in gut 
transit. The authors concluded that prolongation of 
WGTT would increase the percentage of deoxycholate 
(DCA) in the bile acid pool, favoring gallstone formation. 
Although this premise is attractive, several method- 
ological problems with the study necessitate further 
study. First, the authors found significant overlap in 
WGTT: More than 50% of non-gallstone-forming sub- 
jects had WGTT values in the range of the gallstone 
patients. If the subjects whose WGTTs were estimated 
were excluded, no major difference could be discerned 
between the two groups. Also, none of the patients had 
an extensive history of dietary factors that in themselves 
could alter lipid and bile acid absorption independently 
of WGTT. Finally, we do not know whether colonic 
transit time, which may prove more important, was 
slowed in non-obese gallstone subjects. Despite these 
methodological problems, the concept is intriguing; 
other studies suggest that alterations in colonic transit 
time may affect the DCA pool size and cholesterol 
saturation index (CSI) (5 ) .  
For instance, delays in colonic transit utilizing agents 
that reduce colonic motility enhance the proportion of 
DCA in the bile acid pool and increase CSI ( 5 ) .  Also, 
feeding DCA or cholic acid, the precursor of DCA, 
increases CSI ( 5 ) .  Conversely, in patients treated with 
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laxatives, wheat bran and intestinal antibiotics, the 
deoxycholate pool is contracted and CSI falls (4,5). Thus 
maneuvers that alter colonic transit affect the DCA pool 
size and CSI. The observation that women of child- 
bearing age also have prolonged transit times and 
greater tendency toward constipation is intriguing in 
light of the observations that this population group is at 
high risk for cholesterol gallstones (6). 
An increased percentage of DCA in the bile acid pool 
has been observed in several studies examining gallstone 
subjects (5). The mechanism whereby DCA increases 
CSI is not entirely certain, although studies indicate 
that excretion of this bile acid causes a greater increase 
in cholesterol output than does an increase in chenode- 
oxycholic acid (CDCA). This difference is explained by 
the fact that DCA is more hydrophobic; this quality may 
cause a greater solubilization of bile canalicular choles- 
terol. An additional mechanism whereby DCA would 
increase CSI is that an increase in DCA pool size is 
generally paralleled by a decrease in the CDCA pool (5). 
Because CDCA has the strongest inhibitory effect on 
cholesterol output, a change in the ratio of DCA to CDCA 
may have significant effects on CSI. In addition to these 
mechanisms, there appears to be a direct correlation 
between the rate of biliary excretion of DCA and 
arachidonic acid content of human biliary lecithin (1). 
Increases in this lipid fraction might enhance prosta- 
glandin synthesis by the gallbladder mucosa. Increased 
prostaglandin levels would increase mucus secretion by 
the gallbladder epithelium, thereby providing a more 
favorable framework for cholesterol nucleation (1). 
Thus colonic factors that increase DCA pool size may 
enhance cholesterol gallstone formation by several 
mechanisms. 
Should we now add prolonged WGTT to the well- 
known risk factors for cholesterol gallstones (i.e., 
obesity, female sex, weight-reduction diets, hypertriglyc- 
eridemia and estrogens)? Certainly at this point it is 
difficult to do so. Krevsky et al. (7), using colonic transit 
scintigraphy, noted a lack of correlation between the 
number of bowel movements and the movement of feces 
through the colon. They suggest that studies counting 
the number of bowel movements or quantitating 
markers may not accurately reflect colonic transit. 
Improved methodologies that allow investigation to 
correlate colonic transit time with biliary bile acid and 
lipid composition would help answer this question. 
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ABSTRACT 
Objective: To determine clinical and economic con- 
sequences of alternative vaccination strategies for 
preventing hepatitis B virus infection (HBV). 
Methods: Decision analysis was used to evaluate 
costs, outcomes, and cost-effectiveness of three HBV 
management strategies (“no vaccination,” “universal 
vaccination,” and “screen and vaccinate”) in four 
populations (newborns, 10-year-old adolescents, a 
high-risk adult population, and the general adult U.S. 
population). Information on HBV incidence and prev- 
alence, clinical course, and management of acute 
illness and chronic sequelae was obtained from the 
literature and a panel of experts. Actual payments 
(costs) were obtained from Blue CrossiBlue Shield and 
local pharmacies. Incremental cost-effectiveness was 
calculated from the perspective of the payer of medical 
care and subjected to sensitivity analysis. 
Results: Vaccination (with or without screening) 
prevents more disease at somewhat increased cost 
than no vaccination for the neonatal, adolescent, and 
adult populations. Vaccination (with or without 
screening) is a dominant strategy in adult high-risk 
populations (lower cost and greater benefit than no 
vaccination). Optimal cost-effectiveness, with non- 
monetary benefits not discounted, results if all 
pregnant women are screened for active HBV in- 
fection, and HBV vaccine and hepatitis B immune 
globulin are administered to babies born to mothers 
with positive screening tests. Then HBV vaccine is 
administered to all children at age 10 and again 10 
years later (incremental cost-per-year-of-life-saved rel- 
ative to the “no vaccination” strategy is $375). A 
strategy of universal newborn vaccination alone leads 
to an incremental cost-per-year-of-life saved of $3332. 
If adolescents are vaccinated at age 10, incremental 
cost-per-year-of-life saved is $13,938; for the general 
adult population, the incremental cost-per-year-of-life 
saved of universal vaccination is $54,524. Discounting 
benefits will increase cost-per-year-of-life saved 7 to 12 
times for all strategies. 
Conclusions: HBV vaccine is most cost-effective 
